Asymptomatic (benign) monoclonal gammopathy; a study of 100 patients

A. I. Pick, Y. Shoenfeld, F. Skvaril, S. Schreibman, R. Fröhlichman, H. Weiss, J. Pinkhas

Research output: Contribution to journalArticlepeer-review


The clinical and laboratory findings in 100 patients with asymptomatic (benign) monoclonal gammopathy (AMG), followed for a period of 3 to 14 yrs, are summarized and compared to similar findings in 60 patients with clinically overt multiple myeloma (MM). Owing to the difficulty in the early distinction between AMG and MM in patients without osteolytic bone lesions and Bence Jones proteinuria, the differences found in these 2 groups of patients were statistically evaluated. In the absence of clinical findings such as bone pain and Bence Jones proteinuria, the following immunologic differences were found: AMG patients had stable monoclonal components with a mean concentration of 2103 ± 803 mg per dl versus 4170 ± 2550 mg per dl for myeloma patients, while the polyclonal IgA and IgM concentrations were higher in AMG patients who also had a higher incidence of lambda light chains (ratio 1:1.1 versus 2:1 for MM patients). A most significant, previously unreported finding was a predominance of monoclonal components of the IgG-1 subclass in AMG patients and the IgG-3 subclass in MM patients. The findings distinguishing these 2 entities are summarized in a profile based on the differences observed in certain AMG and MM patients in the early, pre-clinical stage of their disease.

Original languageEnglish
Pages (from-to)335-343
Number of pages9
JournalAnnals of Clinical and Laboratory Science
Issue number4
StatePublished - 1977
Externally publishedYes


Dive into the research topics of 'Asymptomatic (benign) monoclonal gammopathy; a study of 100 patients'. Together they form a unique fingerprint.

Cite this